Literature DB >> 25352098

PRC2 loss amplifies Ras signaling in cancer.

Annika Baude1, Anders M Lindroth2, Christoph Plass1.   

Abstract

The histone-modifying PRC2 complex has an ambiguous role in cancer, bearing both oncogenic and tumor-suppressive features depending on cell type. Studies of malignant peripheral nerve sheath tumors (MPNSTs) have now identified loss-of-function mutations altering PRC2 subunits, leading to the amplification of Ras-driven transcription and conferring vulnerability to BRD4 inhibitors.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25352098     DOI： 10.1038/ng.3124

Source DB:  PubMed          Journal:  Nat Genet        ISSN： 1061-4036            Impact factor:   38.330


  14 in total

Review 1.  Transcriptional regulation by Polycomb group proteins.

Authors:  Luciano Di Croce; Kristian Helin
Journal:  Nat Struct Mol Biol       Date:  2013-10       Impact factor: 15.369

2.  Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients.

Authors:  T N Basu; D H Gutmann; J A Fletcher; T W Glover; F S Collins; J Downward
Journal:  Nature       Date:  1992-04-23       Impact factor: 49.962

Review 3.  EZH2 as a potential target in cancer therapy.

Authors:  Michael T McCabe; Caretha L Creasy
Journal:  Epigenomics       Date:  2014-06       Impact factor: 4.778

4.  Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells.

Authors:  Dimitrios Iliopoulos; Marianne Lindahl-Allen; Christos Polytarchou; Heather A Hirsch; Philip N Tsichlis; Kevin Struhl
Journal:  Mol Cell       Date:  2010-09-10       Impact factor: 17.970

5.  MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.

Authors:  Walter J Jessen; Shyra J Miller; Edwin Jousma; Jianqiang Wu; Tilat A Rizvi; Meghan E Brundage; David Eaves; Brigitte Widemann; Mi-Ok Kim; Eva Dombi; Jessica Sabo; Atira Hardiman Dudley; Michiko Niwa-Kawakita; Grier P Page; Marco Giovannini; Bruce J Aronow; Timothy P Cripe; Nancy Ratner
Journal:  J Clin Invest       Date:  2012-12-10       Impact factor: 14.808

6.  Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma.

Authors:  Peter W Lewis; Manuel M Müller; Matthew S Koletsky; Francisco Cordero; Shu Lin; Laura A Banaszynski; Benjamin A Garcia; Tom W Muir; Oren J Becher; C David Allis
Journal:  Science       Date:  2013-03-28       Impact factor: 47.728

7.  Characterization of an antagonistic switch between histone H3 lysine 27 methylation and acetylation in the transcriptional regulation of Polycomb group target genes.

Authors:  Diego Pasini; Martina Malatesta; Hye Ryung Jung; Julian Walfridsson; Anton Willer; Linda Olsson; Julie Skotte; Anton Wutz; Bo Porse; Ole Nørregaard Jensen; Kristian Helin
Journal:  Nucleic Acids Res       Date:  2010-04-12       Impact factor: 16.971

8.  Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors.

Authors:  Ming Zhang; Yuxuan Wang; Sian Jones; Mark Sausen; Kevin McMahon; Rajni Sharma; Qing Wang; Allan J Belzberg; Kaisorn Chaichana; Gary L Gallia; Ziya L Gokaslan; Greg J Riggins; Jean-Paul Wolinksy; Laura D Wood; Elizabeth A Montgomery; Ralph H Hruban; Kenneth W Kinzler; Nickolas Papadopoulos; Bert Vogelstein; Chetan Bettegowda
Journal:  Nat Genet       Date:  2014-10-12       Impact factor: 38.330

9.  Selective inhibition of BET bromodomains.

Authors:  Panagis Filippakopoulos; Jun Qi; Sarah Picaud; Yao Shen; William B Smith; Oleg Fedorov; Elizabeth M Morse; Tracey Keates; Tyler T Hickman; Ildiko Felletar; Martin Philpott; Shonagh Munro; Michael R McKeown; Yuchuan Wang; Amanda L Christie; Nathan West; Michael J Cameron; Brian Schwartz; Tom D Heightman; Nicholas La Thangue; Christopher A French; Olaf Wiest; Andrew L Kung; Stefan Knapp; James E Bradner
Journal:  Nature       Date:  2010-09-24       Impact factor: 49.962

10.  PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors.

Authors:  William Lee; Sewit Teckie; Thomas Wiesner; Leili Ran; Carlos N Prieto Granada; Mingyan Lin; Sinan Zhu; Zhen Cao; Yupu Liang; Andrea Sboner; William D Tap; Jonathan A Fletcher; Kety H Huberman; Li-Xuan Qin; Agnes Viale; Samuel Singer; Deyou Zheng; Michael F Berger; Yu Chen; Cristina R Antonescu; Ping Chi
Journal:  Nat Genet       Date:  2014-09-21       Impact factor: 38.330
View more
  12 in total

Review 1.  Targeting EZH2 and PRC2 dependence as novel anticancer therapy.

Authors:  Bowen Xu; Kyle D Konze; Jian Jin; Gang Greg Wang
Journal:  Exp Hematol       Date:  2015-05-28       Impact factor: 3.084

Review 2.  H3K27 Methylation: A Focal Point of Epigenetic Deregulation in Cancer.

Authors:  J N Nichol; D Dupéré-Richer; T Ezponda; J D Licht; W H Miller
Journal:  Adv Cancer Res       Date:  2016-06-17       Impact factor: 6.242

Review 3.  TUG1: a pivotal oncogenic long non-coding RNA of human cancers.

Authors:  Zheng Li; Jianxiong Shen; Matthew T V Chan; William Ka Kei Wu
Journal:  Cell Prolif       Date:  2016-06-23       Impact factor: 6.831

Review 4.  Targeting EZH2 in cancer.

Authors:  Kimberly H Kim; Charles W M Roberts
Journal:  Nat Med       Date:  2016-02       Impact factor: 53.440

5.  Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics.

Authors:  Inga-Marie Schaefer; Christopher Dm Fletcher; Jason L Hornick
Journal:  Mod Pathol       Date:  2015-11-20       Impact factor: 7.842

Review 6.  Epigenetic mechanisms drive the progression of neurofibromas to malignant peripheral nerve sheath tumors.

Authors:  Krish Suresh; Tamara Kliot; Andrea Piunti; Michel Kliot
Journal:  Surg Neurol Int       Date:  2016-11-14

Review 7.  Oncogenic roles of enhancer of zeste homolog 1/2 in hematological malignancies.

Authors:  Makoto Nakagawa; Issay Kitabayashi
Journal:  Cancer Sci       Date:  2018-06-27       Impact factor: 6.716

Review 8.  Symphony of epigenetic and metabolic regulation-interaction between the histone methyltransferase EZH2 and metabolism of tumor.

Authors:  Tengrui Zhang; Yueqing Gong; Hui Meng; Chen Li; Lixiang Xue
Journal:  Clin Epigenetics       Date:  2020-05-24       Impact factor: 6.551

9.  Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.

Authors:  Jennifer Varin; Laury Poulain; Mikael Hivelin; Patrick Nusbaum; Arnaud Hubas; Ingrid Laurendeau; Laurent Lantieri; Pierre Wolkenstein; Michel Vidaud; Eric Pasmant; Nicolas Chapuis; Béatrice Parfait
Journal:  Oncotarget       Date:  2016-06-14

10.  suz12 inactivation in p53- and nf1-deficient zebrafish accelerates the onset of malignant peripheral nerve sheath tumors and expands the spectrum of tumor types.

Authors:  Felix Oppel; Dong H Ki; Mark W Zimmerman; Kenneth N Ross; Ting Tao; Hui Shi; Shuning He; Jon C Aster; A Thomas Look
Journal:  Dis Model Mech       Date:  2020-08-27       Impact factor: 5.758
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.